Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors

被引:46
|
作者
Zortea, Karine [1 ,2 ]
Franco, Viviane C. [1 ,2 ]
Francesconi, Lenise P. [1 ,2 ]
Cereser, Keila M. M. [1 ,2 ]
Lobato, Maria Ines R. [1 ,2 ]
Belmonte-de-Abreu, Paulo S. [1 ,2 ]
机构
[1] Hosp Clin Porto Alegre, Schizophrenia Program, BR-90035903 Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, Postgrad Program Med Psychiat, BR-90035903 Porto Alegre, RS, Brazil
来源
NUTRIENTS | 2016年 / 8卷 / 02期
关键词
cardiovascular disease; cholesterol; resveratrol; schizophrenia; METAANALYSIS;
D O I
10.3390/nu8020073
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Patients with schizophrenia (SZ) are generally overweight or obese and have several metabolic disorders. Additionally, such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease (CVD). The objective of this study was to determine the efficacy of resveratrol supplementation on serum glucose and CVD risk factors in individuals with SZ. Methods and Results: This is a four-week randomized, double-blind controlled trial (registration No.: NCT 02062190) in which 19 men with a diagnosis of SZ, aged 18 to 65, were assigned to either a resveratrol supplement group (200 mg/day) or a placebo group (200 mg/day). In short, we did not observe significant changes after resveratrol supplementation. In the placebo group, we found a significant increase in total cholesterol levels (p = 0.024) and in LDL-cholesterol (p = 0.002), as well as a decrease in body fat percentage (p = 0.038). The placebo group also showed an increase in triglycerides (9.19%) and a reduction in HDL-cholesterol (4.88%). In the resveratrol group, triglycerides decreased (7.64%). Conclusion: In summary, oral resveratrol in reasonably low dosages (200 mg daily) brought no differences to body weight, waist circumference, glucose, and total cholesterol. It was possible to note that the lipid profile in the placebo group worsened and, although no significant differences were found, we can assume that resveratrol might prevent lipid profile damage and that the intervention affected the lipoprotein metabolism at various levels.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] δ-Tocotrienol in Combination with Resveratrol Improves the Cardiometabolic Risk Factors and Biomarkers in Patients with Metabolic Syndrome: A Randomized Controlled Trial
    Fatima, Safia
    Khan, Dilshad Ahmad
    Aamir, Muhammad
    Pervez, Muhammad Amjad
    Fatima, Fozia
    METABOLIC SYNDROME AND RELATED DISORDERS, 2023, 21 (01) : 25 - 34
  • [22] The Role of Antioxidants Supplementation in Clinical Practice: Focus on Cardiovascular Risk Factors
    Cammisotto, Vittoria
    Nocella, Cristina
    Bartimoccia, Simona
    Sanguigni, Valerio
    Francomano, Davide
    Sciarretta, Sebastiano
    Pastori, Daniele
    Peruzzi, Mariangela
    Cavarretta, Elena
    D'Amico, Alessandra
    Castellani, Valentina
    Frati, Giacomo
    Carnevale, Roberto
    ANTIOXIDANTS, 2021, 10 (02) : 1 - 32
  • [23] Evaluating the Efficacy of Resveratrol-Containing Mouthwash as an Adjunct Treatment for Periodontitis: A Randomized Clinical Trial
    Mohammed, Sura A.
    Akram, Hadeel Mazin
    EUROPEAN JOURNAL OF DENTISTRY, 2024,
  • [24] Assessment of cardiovascular disease risk factors in patients treated for schizophrenia
    Tylec, Aneta
    Skalecki, Maciej
    Ziemecki, Piotr
    Brzozowska, Agnieszka
    Dubas-Slemp, Halina
    Kucharska, Katarzyna
    PSYCHIATRIA POLSKA, 2019, 53 (06) : 1305 - 1319
  • [25] Impact of resveratrol supplementation on clinical parameters and inflammatory markers in patients with chronic periodontitis: a randomized clinical trail
    Shabnam Nikniaz
    Farzane Vaziri
    Reza Mansouri
    BMC Oral Health, 23
  • [26] Impact of resveratrol supplementation on clinical parameters and inflammatory markers in patients with chronic periodontitis: a randomized clinical trail
    Nikniaz, Shabnam
    Vaziri, Farzane
    Mansouri, Reza
    BMC ORAL HEALTH, 2023, 23 (01)
  • [27] Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Li, Xinmin
    Long, Junzi
    Gao, Qian
    Pan, Mengyang
    Wang, Jing
    Yang, Fangjie
    Zhang, Yasu
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2023, 24 (08)
  • [28] Bromelain and Cardiovascular Risk Factors in Diabetes:An Exploratory Randomized,Placebo Controlled,Double Blind Clinical Trial
    黎七妹
    倪青
    廖星
    高怀林
    Nicola Robinson
    Chinese Journal of Integrative Medicine, 2016, 22 (10) : 728 - 737
  • [29] Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial
    Chit Moy Ley
    Qing Ni
    Xing Liao
    Huai-lin Gao
    Nicola Robinson
    Chinese Journal of Integrative Medicine, 2016, 22 : 728 - 737
  • [30] The effect of almonds on vitamin E status and cardiovascular risk factors in Korean adults: a randomized clinical trial
    Jung, Hana
    Chen, C. -Y. Oliver
    Blumberg, Jeffrey B.
    Kwak, Ho-Kyung
    EUROPEAN JOURNAL OF NUTRITION, 2018, 57 (06) : 2069 - 2079